Enzymatic therapy for celiac

Enzymatic therapy for celiac disease applies engineered enzymes and enzyme-targeting inhibitors to protect celiac patients from the autoimmune intestinal damage triggered by dietary gluten, as a pharmaceutical complement to the lifelong gluten-free diet that remains the only established treatment. Researchers at the University of Barcelona and the Institut de Biologia Molecular de Barcelona (IBMB-CSIC) designed “celiacase,” a recombinant enzyme active at gastric pH that works synergistically with pepsin to degrade gluten immunogenic peptides — including the highly reactive 33-mer fragment from wheat alpha-gliadin — before they reach the duodenum, reducing intestinal atrophy, inflammation, antibody response and dysbiosis at low doses in mouse models; the molecule is patented and a spin-off is being formed to advance it toward clinical use. In Germany, Dr. Falk Pharma has funded university research on ZED1227, an oral inhibitor of transglutaminase 2 (TG2) — the enzyme that deamidates gluten peptides and triggers the celiac immune cascade — which in a 2024 study protected patients consuming 3 grams of daily gluten for six weeks from measurable intestinal mucosal damage and inflammation at a 100 mg daily dose. On the commercial supplement side, DSM-Firmenich markets Tolerase G, an Aspergillus niger-derived prolyl endoprotease (AN-PEP) sold as a dietary-supplement ingredient to support digestion of incidental gluten exposure, though it lacks the same clinical-trial evidence base as the prescription-track candidates. In the US, Seattle’s PvP Biologics developed KumaMax, an oral enzyme designed to break down immune-reactive gluten in the stomach, under a 2016 deal in which Takeda committed $35 million in R&D funding plus an option to acquire PvP; the program advanced into Takeda’s pipeline as zamaglutenase (TAK-062), and industry reporting indicates its later-stage trial showed increased mucosal damage rather than protection, after which the program was discontinued.

The key directions of enzymatic therapy for celiac are:

1. Gastric-active gluten-degrading enzymes (Gastric-Active Gluten-Degrading Enzymes): engineered or recombinant proteases active at low stomach pH that degrade immunogenic gluten peptides before they reach the duodenum.
2. Transglutaminase-2 (TG2) inhibition (Transglutaminase-2 (TG2) Inhibition): small-molecule inhibitors blocking the enzyme that deamidates gluten peptides and triggers the autoimmune cascade, rather than degrading gluten itself.
3. Oral supplement-grade digestive enzymes (Oral Supplement-Grade Digestive Enzymes): commercially marketed enzyme blends intended to aid incidental gluten digestion, sold without the same clinical evidence bar as prescription-track therapeutics.
4. Staged biotech-to-pharma enzyme partnerships (Staged Biotech-to-Pharma Enzyme Partnerships): large pharmaceutical companies funding a smaller biotech’s engineered-enzyme platform through milestone-based option-to-acquire deals.

Sectoral value chain#

[enzyme/inhibitor design] ──> [preclinical validation] ──> [clinical gluten-challenge trial] ──> [efficacy/safety evaluation]
                                                                              │
                                                                       (regulatory decision
                                                                        or program halt)
                                                                              │
                                                                              ▼
[patient use/sale] <─── [commercial/OTC formulation] <─────────────────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Recombinant gastric-active proteases (Recombinant Gastric-Active Proteases): enzymes engineered for peak activity at gastric pH, synergizing with native pepsin to pre-digest immunogenic gluten fragments.
• Transglutaminase-2 inhibitor chemistry (Transglutaminase-2 Inhibitor Chemistry): small molecules blocking the deamidation step that increases gluten peptides’ affinity for HLA-DQ2/DQ8 antigen presentation.
• Prolyl endopeptidase supplementation (Prolyl Endopeptidase Supplementation): Aspergillus niger-derived AN-PEP enzymes marketed as digestive aids for incidental gluten exposure.

The stack spans gastric-active enzyme engineering, enzyme-target inhibition and commercial OTC enzyme supplementation.

1. Gastric-active recombinant proteases (Gastric-Active Recombinant Proteases):
   • engineered proteins reach maximum activity at gastric pH (~2), working alongside native pepsin to degrade immunogenic gluten peptides before they reach the duodenum, then self-inactivating in the intestine.
   • case: the University of Barcelona/IBMB-CSIC’s celiacase reduced intestinal atrophy, inflammation, antibody response and dysbiosis at low doses in mouse models.
2. TG2-inhibitor small-molecule chemistry (TG2-Inhibitor Small-Molecule Chemistry):
   • blocking transglutaminase 2 prevents the deamidation step that increases gluten peptides’ binding affinity to HLA-DQ2/DQ8, upstream of the immune cascade rather than degrading gluten directly.
   • case: Dr. Falk Pharma-funded ZED1227 protected patients from measurable mucosal damage and inflammation during a 6-week, 3g/day gluten challenge at 100mg daily.
3. Engineered oral gluten-degrading enzymes (Engineered Oral Gluten-Degrading Enzymes):
   • a recombinant enzyme engineered to break down immune-reactive gluten fragments in the stomach before intestinal exposure.
   • case: PvP Biologics/Takeda’s zamaglutenase (TAK-062) degraded 6 grams of gluten in a Phase 1 study, though a later trial stage reportedly showed worsened mucosal damage, illustrating the difficulty of ensuring degradation byproducts remain non-immunogenic at scale.